Abstract:Research demonstrates that the neural mechanisms underlying synaptic plasticity and learning and memory involve mobilization of AMPA-type neurotransmitter receptors at glutamatergic synaptic contacts, and that these mechanisms are targeted during neurodegenerative disease. Strengthening neural transmission occurs with insertion of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs) into synapses while weakening results from receptor withdrawal. A key player in the trafficking of AMPARs during plasticity and learning is the brain-derived neurotrophic factor (BDNF) signaling system. BDNF is a neurotrophic factor that supports neuronal growth and is required for learning and memory. Significantly, a primary feature of many neurodegenerative diseases is a reduction in BDNF protein as well as disrupted neuronal surface expression of synaptic AMPARs. The resulting weakening of synaptic contacts leads to synapse loss and neuronal degeneration that underlies the cognitive impairment and dementia observed in patients with progressive neurodegenerative disease such as Alzheimer's. In the face of these data, one therapeutic approach is to increase BDNF bioavailability in brain. While this has been met with significant challenges, the results of the research have been promising. In spite of this, there are currently no clinical trials to test many of these findings on patients. Here, research showing that BDNF drives AMPARs to synapses, AMPAR trafficking is essential for synaptic plasticity and learning, and that neurodegenerative disease results in a significant decline in BDNF will be reviewed. The aim is to draw attention to the need for increasing patient-directed clinical studies to test the possible benefits of increasing levels of neurotrophins, specifically BDNF, to treat brain disorders. Much is known about the cellular mechanisms that underlie learning and memory in brain. It can be concluded that signaling by neurotrophins like BDNF and AMPA-type glutamate receptor synaptic trafficking are fundamental to these processes. Data from animal models and patients reveal that these mechanisms are adversely targeted during neurodegenerative disease and results in memory loss and cognitive decline. A brief summary of our understanding of these mechanisms indicates that it is time to apply this knowledge base directly to development of therapeutic treatments that enhance neurotrophins for brain disorders in patient populations.

Master regulators of neurogenesis: the dynamic roles of Ephrin receptors across diverse cellular niches

A Negative Regulator of Synaptic Development: MDGA and Its Links to Neurodevelopmental Disorders

Essential Roles of EphrinB2 in Mammalian Heart: from Development to Diseases.

Protease Regulation: the Yin and Yang of Neural Development and Disease

The Eph family in the patterning of neural development

The role of glial and neuronal Eph/ephrin signaling in Drosophila mushroom body development and sleep and circadian behavior

Harnessing the master transcriptional repressor REST to reciprocally regulate neurogenesis

Eph receptor signalling: from catalytic to non-catalytic functions

Radixin: Roles in the Nervous System and Beyond

Optogenetic Regulation of EphA1 RTK Activation and Signaling

New Insights into Reelin-Mediated Signaling Pathways

BDNF signaling in context: From synaptic regulation to psychiatric disorders

Targeting the neural extracellular matrix in neurological disorders

Neurotrophin regulation of neural circuit development and function

Ras, RhoA, and vascular pharmacology in neurodevelopment and aging

Adult Neural Stem Cell Regulation by Small Non-coding RNAs: Physiological Significance and Pathological Implications

Regulation of AMPAR trafficking in synaptic plasticity by BDNF and the impact of neurodegenerative disease

Eph/ephrin signalling in the developing brain is regulated by tissue stiffness

Regulation of Neuromodulator Receptor Efficacy - Implications for Whole-Neuron and Synaptic Plasticity

BDNF and Its Multirole Function in Neurogenesis, Synaptic Transmission and Neurodegenerative Diseases

SPROUTY2, a Negative Feedback Regulator of Receptor Tyrosine Kinase Signaling, Associated with Neurodevelopmental Disorders: Current Knowledge and Future Perspectives